iSTAR Medical Expands Commercial Rollout With First MINIject Surgeries in Switzerland

iSTAR Medical announced that it has continued its commercial rollout expansion for MINIject® to Switzerland. MINIject® is iSTAR Medical’s MIGS implant and currently the only commercially available supraciliary MIGS device, according to the company. Swiss patients with open-angle glaucoma are now able to benefit from MINIject®, which has demonstrated meaningful and sustained performance, combined with a favorable safety profile. The first implants with MINIject® have now been successfully completed at Swiss Visio, Clinique de Montchoisi, Lausanne by Kaweh Mansouri, MD, MPH, and Inselspital, Bern by Jan Darius Unterlauft, MD. This follows iSTAR Medical’s recent expansion of MINIject® into the United Kingdom in March.

“Glaucoma is a growing problem in the increasingly ageing Swiss population, with glaucoma incidence rising from 2% of people over the age of 50 to 5-8% in those over 70. Access to MINIject will now enable me to offer a novel and safe minimally-invasive surgical approach to my patients, deferring more invasive surgery, and preserving vision for longer,” said Dr. Mansouri.

“I am delighted to be able to offer MINIject to patients currently living with open-angle glaucoma. This innovative MIGS device, with its distinctive STAR material, provides a clear benefit to my patients to achieve the right balance of meaningful intraocular pressure reduction with favourable safety, sustained over the longer term,” said Dr. Unterlauft.

“Following our recent expansion in the UK, our roll out into Switzerland further realizes our commitment to provide patients and surgeons across Europe access to MINIject, currently the only commercially available MIGS device targeting the supraciliary space. With the timely addition of Switzerland, we are on track in our mission to preserve the vision of glaucoma patients throughout Europe," said Michel Vanbrabant, CEO of iSTAR Medical.